ALKERMES ($ALKS) posted quarterly earnings results for Q4 2025 on Wednesday, February 25th. The company reported earnings of $0.46 per share, beating estimates of $0.34 by $0.12. The company also reported revenue of $384,550,000, missing estimates of $389,485,439 by $-4,935,439.
You can see Quiver Quantitative's $ALKS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALKERMES Insider Trading Activity
ALKERMES insiders have traded $ALKS stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $ALKS stock by insiders over the last 6 months:
- SHANE COOKE has made 0 purchases and 2 sales selling 61,200 shares for an estimated $2,115,672.
- CRAIG C. HOPKINSON (EVP R&D, Chief Medical Officer) has made 0 purchases and 8 sales selling 43,748 shares for an estimated $1,354,254.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ALKERMES Hedge Fund Activity
We have seen 185 institutional investors add shares of ALKERMES stock to their portfolio, and 203 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP removed 3,009,933 shares (-64.3%) from their portfolio in Q4 2025, for an estimated $84,217,925
- WELLINGTON MANAGEMENT GROUP LLP added 2,645,252 shares (+705.0%) to their portfolio in Q4 2025, for an estimated $74,014,150
- HOLOCENE ADVISORS, LP removed 2,469,030 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $69,083,459
- DEEP TRACK CAPITAL, LP added 2,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $55,960,000
- BAKER BROS. ADVISORS LP added 1,920,916 shares (+23.7%) to their portfolio in Q4 2025, for an estimated $53,747,229
- UBS GROUP AG added 1,790,729 shares (+237.4%) to their portfolio in Q4 2025, for an estimated $50,104,597
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,719,334 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $48,106,965
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ALKERMES Analyst Ratings
Wall Street analysts have issued reports on $ALKS in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 11/17/2025
- Wells Fargo issued a "Overweight" rating on 11/13/2025
- Deutsche Bank issued a "Buy" rating on 11/13/2025
- Needham issued a "Buy" rating on 10/29/2025
- Mizuho issued a "Outperform" rating on 10/27/2025
- Piper Sandler issued a "Overweight" rating on 10/23/2025
- RBC Capital issued a "Outperform" rating on 09/26/2025
To track analyst ratings and price targets for ALKERMES, check out Quiver Quantitative's $ALKS forecast page.
ALKERMES Price Targets
Multiple analysts have issued price targets for $ALKS recently. We have seen 11 analysts offer price targets for $ALKS in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Rudy Li from Wolfe Research set a target price of $45.0 on 02/24/2026
- Jason Gerberry from B of A Securities set a target price of $34.0 on 02/20/2026
- Joon Lee from Truist Securities set a target price of $55.0 on 11/17/2025
- David Hoang from Deutsche Bank set a target price of $45.0 on 11/13/2025
- Benjamin Burnett from Wells Fargo set a target price of $37.0 on 11/13/2025
- Ami Fadia from Needham set a target price of $44.0 on 10/29/2025
- Uy Ear from Mizuho set a target price of $45.0 on 10/27/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
